Efficacy and Safety of Decitabine Combined with Modified EIAG Regimen in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

• Published in: Zhongguo shi yan xue ye xue za zhi Vol. 31; no. 2; p. 338
• Main Authors: Mao, Jian-Ping, Xue, Lian-Guo, Zhu, Yuan-Xin, Jia, Tao, Wang, Ying, Miao, Lei, Wei, Ji-Feng, Zhao, Li-Dong
• Format: Journal Article
• Language: Chinese
• Published: China 01.04.2023
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone Marrow Diseases - drug therapy; Cytarabine; Decitabine - therapeutic use; Humans; Leukemia, Myeloid, Acute - drug therapy; Myelodysplastic Syndromes - drug therapy; Retrospective Studies; Treatment Outcome; EIAG regimen; relapsed/refractory acute myeloid leukemia; decitabine; myelodysplastic syndrome
• ISSN: 1009-2137
• DOI: 10.19746/j.cnki.issn.1009-2137.2023.02.005

To investigate the efficacy, prognosis and safety of decitabine combined with modified EIAG regimen in the treatment of patients with relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The clinical data of 44 patients with relapsed/refractory AML and high-risk MDS admitted to our hospital from January 2017 to December 2020 were analyzed retrospectively. The patients were equally divided into D-EIAG group (decitabine combined with EIAG regimen) and D-CAG group (decitabine combined with CAG regimen) according to clinical treatment regimen. The complete response (CR), CR with incomplete hematologic recover (CRi), morphologic leukemia-free state (MLFS), partial response (PR), overall response rate (ORR), modified composite complete response (mCRc), overall survival (OS) time, 1-year OS rate, myelosuppression and adverse reactions between the two groups were compared. In D-EIAG group, 16 patients (72.7%) achieved mCRc (CR+CRi+MLFS), 3 patients (13.6%) achieved PR, and OR